A5039756526- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pharmaceutical Economics and Policy
- Diabetes Management and Research
- Diabetes Treatment and Management
- Diet and metabolism studies
- RNA and protein synthesis mechanisms
- Health Systems, Economic Evaluations, Quality of Life
- Blood Pressure and Hypertension Studies
- RNA modifications and cancer
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Magnesium in Health and Disease
- Cancer, Lipids, and Metabolism
- DNA and Nucleic Acid Chemistry
- Hepatitis C virus research
- Glycogen Storage Diseases and Myoclonus
- Fibroblast Growth Factor Research
- Metabolism, Diabetes, and Cancer
- Pancreatic function and diabetes
- Computational Drug Discovery Methods
- Biochemical and Molecular Research
- Cardiovascular Function and Risk Factors
- Chronic Kidney Disease and Diabetes
- Chronic Lymphocytic Leukemia Research
- Colorectal Cancer Treatments and Studies
Hunter Holmes McGuire VA Medical Center
2004-2020
Virginia Commonwealth University
1996-2010
University of Richmond
2007-2010
Veterans Health Administration
1995-2004
Virginia Commonwealth University Medical Center
1987-1998
United States Department of Veterans Affairs
1969-1998
University of Minnesota
1969-1978
Wake Forest University
1975
Atrium Health Wake Forest Baptist
1975
Eunice Kennedy Shriver National Institute of Child Health and Human Development
1973
The effects of intensive glucose control on cardiovascular events in patients with long-standing type 2 diabetes mellitus remain uncertain.We randomly assigned 1791 military veterans (mean age, 60.4 years) who had a suboptimal response to therapy for receive either or standard control. Other risk factors were treated uniformly. mean number years since the diagnosis was 11.5, and 40% already event. goal intensive-therapy group an absolute reduction 1.5 percentage points glycated hemoglobin...
•Statin intolerance limits many patients from achieving optimal low-density lipoprotein cholesterol concentrations.•Alirocumab reduced levels more than ezetimibe in statin-intolerant patients.•Alirocumab led to fewer skeletal muscle adverse events compared with atorvastatin. BackgroundStatin (LDL-C) concentrations. Current options for such include using a lower but tolerated dose of statin and adding or switching other non-statin therapies.MethodsODYSSEY ALTERNATIVE (NCT01709513) alirocumab...
Abstract The rate and extent of GTP hydrolysis by a molar excess ribosomes G factor (the soluble translocation protein) are unaffected fusidic acid. When the nucleotide substrate level is increased to exceed macromolecular components, there burst acid-resistant approximately equivalent amount when present in excess. Neither nor alone capable catalyzing even 1 eq hydrolysis. Several methods were used show that at initial concentrations as low 10-8 m lowest discrimination) essentially all...
The conditions necessary for the formation and detection of a ribosome-G factor (the soluble translocation protein)-GDP complex in presence fusidic acid have been examined. Complex has accomplished by sucrose density gradient sedimentation both gel Millipore filtration. latter two methods reveal good correlation, as function concentration, between amount isolatable inhibition GTPase activity G factor-ribosome system antibiotic. requires Mg2+ (10 to 20 mm) but apparently does not require...
The dose-response curves for the production of coma in normal rats by single injections ammonium salts were shifted to left (increased responses smaller doses) presence a subcoma dose fatty acid, and conversely. incidence rose from 0 100% when maximum doses NH4+ sodium octanoate given simultaneously average blood NH3, increased 1042 2585 µg/100 ml. A similar increase was demonstrated replaced hexanoate, decanoate or oleate. levels plasma free acids (octanoate) at which occurred lowered...
Objective. —To determine whether implantable insulin pump (IIP) therapy and multiple daily (MDI) injections could equally attain improved blood glucose control, to compare the 2 treatments with respect reducing fluctuations, serious hypoglycemic reactions, improving patients' quality of life. Design. —Randomized clinical trial. Setting. —Seven Veterans Affairs medical centers. Patients. —One hundred twenty-one male type II diabetic patients between ages 40 69 years, receiving at least 1...
To determine whether implantable insulin pump (IIP) therapy and multiple daily (MDI) injections could equally attain improved blood glucose control, to compare the 2 treatments with respect reducing fluctuations, serious hypoglycemic reactions, improving patients' quality of life.Randomized clinical trial.Seven Veterans Affairs medical centers.One hundred twenty-one male type II diabetic patients between ages 40 69 years, receiving at least 1 injection per day having hemoglobin A1c (HbA1c)...
<h3>Background</h3> Combination therapy to improve the total lipid profile may achieve greater coronary risk reductions than lowering low-density lipoprotein cholesterol (LDL-C) alone. A new extended-release niacin (niacin ER)/lovastatin tablet substantially lowers LDL-C, triglyceride, and lipoprotein(a) levels raises high-density (HDL-C) level. We evaluated these serum responses ER/lovastatin at all clinically reasonable doses. <h3>Methods</h3> Men (n = 85) women 79) with type IIa or IIb...
OBJECTIVE To develop a diabetes registry from an outpatient pharmacy database to systematically analyze the prevalence of diabetes, patterns glycemic medication and glucose monitoring, costs, hospital use related care in Veterans Health Administration (VHA) fiscal year (FY) 1994. RESEARCH DESIGN AND METHODS with were identified using software program that extracted social security number (SSN) patients receiving insulin, sulfonylurea agents, or glucose-monitoring supplies. The cumulative...
Few clinical studies have focused on the efficacy of lipid-lowering therapies in patients ≥65 years. After stabilization atorvastatin 10 mg, hypercholesterolemic subjects years at high/very high risk for CHD and not LDL-C <1.81 mmol/L (with atherosclerotic vascular disease [AVD]) or <2.59 (without AVD) were randomized to ezetimibe mg plus uptitration 20 (6 weeks) followed by 40 (additional 6 weeks). A post-hoc analysis compared between-group differences percent attainment individual combined...
A previously healthy member of an aircraft flight crew was acutely incapacitated during with neurologic impairment and gastrointestinal distress. His clinical status returned to normal within 24 hr. The etiology his symptoms related inhalation exposure aerosolized or vaporized synthetic lubricating oil arising from a jet engine aircraft.
Abstract A single intraperitoneal injection of the carcinogenic arylhydroxamic acid N-hydroxy-2-fluorenylacetamide given to male rats inhibited two RNA polymerase activities isolated liver nuclei by as much 80%. Low doses carcinogen Mg2+-dependent activity preferentially; high Mn2+ + (NH4)2SO4-dependent a greater extent. Inhibition was detectable 15 min after compound and maximal in 1 hour. Several related noncarcinogenic compounds acids which were inactive toward completely lacked...
•ODYSSEY ALTERNATIVE assessed alirocumab (ALI) in statin-intolerant patients.•ALI significantly reduced low-density lipoprotein cholesterol during the double-blind treatment period.•The open-label period ALI long-term safety.•Skeletal muscle events were reported by 38.4% of patients with statin-intolerance period.•ALI was well tolerated and produced durable reductions over 3 years. BackgroundThe 24-week randomized, ODYSSEY trial (NCT01709513) demonstrated significant (LDL-C) PCSK9 inhibitor...